{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:37:49Z","timestamp":1782747469905,"version":"3.54.5"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Several studies in the Caucasian population have shown the benefit of using docetaxel, abiraterone, or enzalutamide for patients with metastatic prostate cancer at the castration\u2010resistant stage (mCRPC). However, there are no strong data for men of African ancestry. The objective of this study was to estimate the overall and progression\u2010free survival of patients according to these treatments at the mCRPC stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>This was a monocentric retrospective study that consecutively included 211 men with mCRPC between June 1, 2009 and August 31, 2020. The primary end point was overall survival (OS). The secondary end point was progression\u2010free survival. Kaplan\u2013Meier survival and Cox proportional hazard analyses were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The present study included 180 patients for analyses. There was no difference in OS (log\u2010rank test\u2009=\u20090.73), with a median follow\u2010up of 20.7 months, regardless of the treatment administered in the first line. Men with mCRPC who received hormonotherapy (abiraterone or enzalutamide) showed better progression\u2010free survival than those who received docetaxel (log\u2010rank test\u2009=\u20090.004), with a particular interest for abiraterone hazard ratio (HR)\u2009=\u20090.51 (95% confidence interval: 0.39\u20130.67). The patient characteristics were similar, except for bone lesions, irrespective of the treatment administered in the first line. After univariate then multivariate analysis, only World Health Organization status and metastases at diagnosis were significantly associated with progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results suggest the use of hormonotherapy (abiraterone or enzalutamide) with a tendency for abiraterone in first line for men with African ancestry at the mCRPC stage.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.24270","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T17:38:31Z","timestamp":1637861911000},"page":"269-275","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Overall and progression\u2010free survival of Afro\u2010Caribbean men with metastatic castration\u2010resistant prostate cancer (mCRPC)"],"prefix":"10.1002","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-6334","authenticated-orcid":false,"given":"Pierre\u2010Gilles","family":"Vestris","sequence":"first","affiliation":[{"name":"Service d'Urologie CHU de Pointe\u2010\u00e0\u2010Pitre Pointe\u2010\u00e0\u2010Pitre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Gourtaud","sequence":"additional","affiliation":[{"name":"Service d'Urologie CHU de Pointe\u2010\u00e0\u2010Pitre Pointe\u2010\u00e0\u2010Pitre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Senechal","sequence":"additional","affiliation":[{"name":"Service d'Urologie CHU de Pointe\u2010\u00e0\u2010Pitre Pointe\u2010\u00e0\u2010Pitre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvanne","family":"Sadreux","sequence":"additional","affiliation":[{"name":"Service d'Urologie CHU de Pointe\u2010\u00e0\u2010Pitre Pointe\u2010\u00e0\u2010Pitre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Roux","sequence":"additional","affiliation":[{"name":"Service d'Urologie CHU de Pointe\u2010\u00e0\u2010Pitre Pointe\u2010\u00e0\u2010Pitre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Blanchet","sequence":"additional","affiliation":[{"name":"Service d'urologie CHU de Pointe\u2010\u00e0\u2010Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail) Pointe\u2010\u00e0\u2010Pitre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[{"name":"Service d'urologie CHU de Pointe\u2010\u00e0\u2010Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail) Pointe\u2010\u00e0\u2010Pitre France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191"},{"key":"e_1_2_9_3_1","unstructured":"Donn\u00e9es du registre g\u00e9n\u00e9ral des cancers de Guadeloupe [Internet]. Accessed November 17 2021.https:\/\/lesdonnees.e-cancer.fr\/Fiches-Indicateurs\/Registre-General-des-cancers-de-la-Guadeloupe#donnees"},{"key":"e_1_2_9_4_1","unstructured":"La morbidit\u00e9 comp\u00e9titive et son impact sur l'esp\u00e9rance de vie: \u00e9valuation et prise en compte dans la d\u00e9cision th\u00e9rapeutique du cancer localis\u00e9 de la prostate. 2018. Accessed November 17 2021.https:\/\/www.urofrance.org\/base-bibliographique\/la-morbidite-competitive-et-son-impact-sur-lesperance-de-vie-evaluation-et"},{"key":"e_1_2_9_5_1","volume-title":"\u00a0Prostate Cancer","author":"Leslie SW","year":"2021"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2018.08.011"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.046"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2741\/4493"},{"key":"e_1_2_9_10_1","unstructured":"RECIST_1.1.pdf [Internet]. Accessed November 17 2021.http:\/\/www.cepd.fr\/CUSTOM\/RECIST_1.1.pdf"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07780-7"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy072"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.11.004"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.09.026"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.033"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.05.009"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24270","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.24270","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:28:03Z","timestamp":1693196883000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/pros.24270"],"URL":"https:\/\/doi.org\/10.1002\/pros.24270","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"2021-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}